FOLLOW US

In a groundbreaking move set to reshape the investment management software landscape, Clearwater Analytics announced on Monday that it will acquire Enfusion, a leader in software solutions for the hedge fund and investment management sectors, for a staggering $1.5 billion.

A $1.5 Billion Merger: Cash and Stock for Enfusion's Future

Under the terms of the acquisition, Clearwater will purchase Enfusion for $11.25 per share. The deal is structured as a combination of cash and stock, with $5.85 per share being paid in cash and $5.40 per share in Clearwater Class A common stock. In total, Clearwater will pay approximately $760 million in cash and issue between 23 million and 28 million new shares to Enfusion’s shareholders. This monumental transaction, which brings together two industry giants in cloud-native investment management technology, is expected to create a unified platform designed to enhance services for institutional investors worldwide.

Powerhouse Legal Teams Behind the Deal

The deal is the result of efforts by three prestigious law firms. Clearwater has been advised by Kirkland & Ellis LLP, while Enfusion has been represented by Goodwin Procter LLP. Enfusion's special committee also received counsel from Dechert LLP. Clearwater's CEO, Sandeep Sahai, expressed his excitement about the future of the merger. “Today’s announcement is about creating a future where our clients benefit from the synergy of two highly complementary, innovative software leaders," Sahai said. "This acquisition enables seamless data management from the front office to the back office, unlocking powerful network effects that amplify client value."

Two Giants, One Unified Vision

Clearwater, a leading provider of Software-as-a-Service (SaaS) solutions that automate the entire investment lifecycle, is set to integrate Enfusion's real-time, enterprise-wide data capabilities with its own suite of middle and back-office solutions. This integration aims to create a seamless front-to-back platform that will cater to the evolving needs of institutional investors, transforming how investment management is done. Enfusion, a SaaS platform specializing in real-time data for investment managers, has long been known for its versatility, scalability, and deep functionality, serving both traditional and alternative investment sectors. Its CEO, Oleg Movchan, highlighted the potential of the combined forces. "Together with Clearwater, our shared passion for building innovative technologies will accelerate our ability to support our clients' evolving needs, ensuring they stay at the forefront of investment management."

Shareholder Approval and Future Outlook

The deal has garnered the support of Enfusion’s shareholders, with those holding around 45% of the company's total voting power entering into voting and support agreements. The transaction is expected to close in the second quarter of 2025, pending approval by Enfusion’s shareholders, regulatory approval, and the usual closing conditions.

Legal Experts Behind the Deal

Clearwater’s legal team at Kirkland & Ellis was led by corporate partners Constantine Skarvelis, Marshall Shaffer, Jimin He, and Daniel Yip, with additional expertise from debt, tax, and capital markets specialists. Enfusion’s special committee was advised by Dechert’s corporate partners Mark E. Thierfelder, Eric S. Siegel, and Michael S. Darby, along with litigation experts Andrew J. Levander and Rick S. Horvath.